Aus: Deutsche Gesellschaft für Gute Forschungspraxis (DGGF) mit Beiträgen von 32 Experten: GCP Auditing- Methods and Experiences ECV Editio Cantor

Size: px
Start display at page:

Download "Aus: Deutsche Gesellschaft für Gute Forschungspraxis (DGGF) mit Beiträgen von 32 Experten: GCP Auditing- Methods and Experiences ECV Editio Cantor"

Transcription

1

2

3 GCP Auditing Methods and Experiences

4

5 GCP Auditing Methods and Experiences 2nd, revised and expanded edition Edited by the German Society for Good Research Practice (DGGF) EDITIO CANTOR VERLAG AULENDORF (GERMANY)

6 Bibliographic data available from the National Library of Germany ( Deutsche Bibliothek ) This publication is catalogued and indexed in Deutsche Nationalbibliographie of the National Library of Germany; detailed bibliographic data is available on the Internet at GCP Auditing. Methods and Experiences Edited by the German Society for Good Research Practice (DGGF) 2nd edition ISBN pharmind-serie Dokumentation 2007 ECV Editio Cantor Verlag für Medizin und Naturwissenschaften GmbH, Aulendorf (Germany). All rights reserved, especially the right of duplication, distribution and translation for an indefinite period. No part of this publication may be reproduced, stored in a retrieval system, or otherwise without the prior written permission of the publisher. The absence of the registered trademark sign after a name does not mean that the name is not protected by trademark rights. Printed and bound by VeBu Druck + Medien GmbH, Bad Schussenried (Germany)

7 Contents Key Note Address Gabriele Schwarz 7 Preface for the 1st edition Hans Günther Stelzer 9 Preface for the 2nd edition Hans Günther Stelzer 10 Papers Quality Management in Clinical Research and the Value of Audits Rita Hattemer-Apostel 11 Clinical Quality Management in a Medical Department of a Multinational Pharmaceutical Company an Enhanced Approach to Quality Jürgen-Hans Schmidt, Martin Gebauer, and Thorsten Gorbauch 33 Audit Schedule and Project Auditor in a Clinical Project Eva Beate Ansmann, Ilona Fleischhauer, Jürgen-Hans Schmidt, Christine Korbmacher, and Christiane Ehmer 41 Audit of Protocol, Written Information for Study Participants, Informed Consent Form and Case Report Form Wolfgang Krempien and Roland Scharpf 48 The Investigator Site Audit Carmen Julius, Beat Widler, Elfriede Lindauer, and Friederike Spengler 61 Clinical Investigator Audit as Part of the Systems Audit Beat Widler, Elfriede Lindauer, Carmen Julius, and Friederike Spengler 71 Investigator Site Audits by the Sponsor in CRO-Monitored Studies Jürgen-Hans Schmidt and Martin Gebauer 77 Sponsor Audits at Contract Research Organisations (CROs) the CROs Perspective Dagmar Chase and Jürgen-Hans Schmidt 82 5

8 Sponsor Audits at Contract Research Organisations (CROs) the Sponsors Perspective Jürgen-Hans Schmidt and Dagmar Chase 99 Audit in the Analytical Laboratory Ralf Schaltenbrand, Susanne Plate, Volker El-Samalouti, and Karin Renneisen 109 Audits of Specialised Laboratories: Approaches, Problems and Solutions Andreas Edelmann and Michaela Rittberger 124 Audits of Early Phase Clinical Trials and Clinical Pharmacology Units Rita Hattemer-Apostel and John Norton 146 Systems Audits in Pharmacovigilance Michaela Rittberger, Michael Stegemann, and Jürgen-Hans Schmidt 164 Audits in Data Management, Statistics and Medical Writing: Auditing Clinical Databases, Trial Reports and Related Systems Rita Hattemer-Apostel and Wolfgang Reinhardt 188 Validation of Computer Systems in Clinical Trials Peter M. Kaiser, Per-Holger Sanden, and Thomas Badautschek 206 Electronic Data Capture (EDC) in Clinical Trials from a Quality Assurance Perspective Hans Poland 219 Performing and Reporting an Audit Administrative and Technical Aspects Beat Widler, Iris Sobol, and Rudolf Löffel 247 Appendix Acronyms and Abbreviations 259 Glossary 263 Index 283 Authors Addresses 285 6

9 Key Note Address I have the great pleasure of writing this preface and congratulating the authors from the GCP Expert Group of the German Society for Good Research Practice on their 1 st revision of the book GCP Auditing Methods and Experiences. Clinical trial results are the scientific basis for the authorization of new medicinal products as well as for the improvement of therapeutic standards. Good Clinical Practice (GCP) describes on the one hand the ethical principles that have their origin in the Declaration of Helsinki and that aim at ensuring the rights, safety and well-being of the trial subject and on the other hand the scientific standards that ensure the reliability and validity of clinical trial results. Meanwhile the CPMP/ICH/135/95 Note for Guidance on Good Clinical Practice (GCP) has been in force for nearly one decade. This guidance was developed in the early nineties to provide a unified standard for the European Union, the United States and Japan in order to facilitate the mutual acceptance of clinical data intended for submission to regulatory authorities. Commission Directive 2003/63/EC of 25 June 2003 as well as Regulation (EC) No 726/2004 of 31 March 2004 specify that those clinical trials that are performed outside the EU but are destined for the authorisation of a new medicinal product within the EU need to be conducted in accordance with the scientific and ethical principles of GCP to be taken into account during the assessment of an application. Furthermore, Commission Directive 2001/20/EC of 4 April 2001 on clinical trials emphasises that any clinical trials on medicinal products for human use, regardless of their particular purpose and whether they are conducted by commercial or non-commercial sponsors, should be performed in accordance with GCP. In view of the enormous costs of clinical research, compliance with GCP is not only a question of ethics and science but also an economic point to consider. Sponsors as well as their contractual partners are forced to implement effective quality assurance and quality control arrangements in order to meet the growing expectations regarding quality in clinical trials. The numerous GCP deviations that are detected in GCP inspections conducted on behalf of the European Commission demonstrate that compliance with the GCP standards is still a challenge. Audits as one important tool in quality assurance are valued highly by regulatory authorities. 7

10 Audits vary from process to document audits and from systems to project audits. They need to be performed on different facilities and functions ranging from sponsor and investigator site audits, audits of contract research organizations (CROs) responsible for monitoring, data management or pharmacovigilance functions to audits of laboratories. Sponsors must ensure quality assurance in all clinical trial phases from trial design to trial conduct to trial evaluation and reporting. In view of the wide range of different audit types that has to be covered by auditors, ICH GCP explicitly asks for auditors that are qualified by training and experience. However, the expectations on such experience and training are not standardised. In this book, senior auditors are willing to share their individual knowledge and experience with the interested reader and thus the book is sure to become a valuable source for other colleagues in the clinical operations and quality assurance units in pharmaceutical companies, CROs and non-profit research organizations. I wish all readers an insightful learning experience and that this book may contribute to the improvement of quality in clinical trials. Bonn (Germany), May 2007 Gabriele Schwarz Clinical Trials / GCP Inspection Unit Federal Institute for Drugs and Medical Devices 8

11 Preface for the 1st edition During the past decade, it was predominantly the Good Clinical Practice (GCP) regulations that made it possible to reach an unprecedented quality standard in the clinical development of new pharmaceutical products. For the next decade the objective of quality assurance in clinical research and development will not only be to maintain the quality standard achieved but also to further strengthen organisational structures and enhance responsibilities, procedures, processes and resources for the implementation of quality management at all levels of clinical drug development. The GCP Quality Assurance Working Party of the German Society for Good Research Practice (Deutsche Gesellschaft für Gute Forschungspraxis e.v. DGGF) is very much involved in all subjects of quality assurance in clinical research and development. The Working Party also deals with the application and interpretation of guidelines as well as professional statements concerning new draft regulations for clinical trials, and has focused on promoting the exchange of information and views between its members. In this book experienced auditors and colleagues from quality management, all of whom are members of the GCP Quality Assurance Working Party, describe methods and processes of quality assurance and quality management in clinical research and development. Their articles also present aspects of experience gained during numerous auditing years. Principles and standards applied in quality assurance are outlined as well as methods for planning, conducting and analysing audits, providing the reader with an overview of the current standard of quality assurance in clinical drug development. The authors would like to thank ECV Editio Cantor Verlag for their willingness and cooperation in editing this book. Freiburg/Brsg. (Germany), July 2003 Hans Günther Stelzer Head of GCP Quality Assurance Working Party of the DGGF 9

12 Preface for the 2nd edition The first edition of this handbook was already sold out when we decided more than one year ago to publish a second edition which should of course be updated and expanded with some additional facets. Therefore all chapters have been revised, adopting the current legal provisions and EU Directives. Five new chapters have been added: Quality Management in Clinical Research and the Value of Audits. Clinical Quality Management in a Medical Department of a Multinational Pharmaceutical Company. Audits of Specialised Laboratories: Approaches, Problems and Solutions. Audit of Early Phase Clinical Trials and Clinical Pharmacology Units. Electronic Data Capture (EDC) in Clinical Trials from a Quality Assurance Perspective. It should be emphasised that all individual articles represent the opinion of their authors and do not assert other authors claims to agree. I would like to thank the authors for their work enthusiasm and for the meticulous revision of their articles. Special thanks go to Rita Hattemer-Apostel for her support in reviewing and editing the manuscripts and her valuable ideas. We are especially grateful to John Norton for his review of the English texts and translations. Finally, ECV Editio Cantor Verlag and its editorial office deserve our best thanks for their care and expertise in the preparation of this book. We hope that the second edition of this volume will once more become successful as a reference book for clinical operations professionals and quality assurance experts. Freiburg/Brsg. (Germany), July 2007 H. Günther Stelzer Head of GCP Quality Assurance Working Party of the DGGF 10

13 Quality Management in Clinical Research and the Value of Audits Rita Hattemer-Apostel Regulatory authorities expect quality assurance (QA) programmes being established at sponsors and external service providers; however, this should not be the only reason for implementing a proper QA programme. QA audits can help ensure the integrity and validity of clinical trial data from the beginning to the end, from trial planning until the final study report through auditing. Audits assess if studies are conducted in an ethical manner, if the trial participants safety and well-being is respected, if the clinical data is valid and the trials are accurately reported. This chapter sets out to provide a profound basis on quality management aspects in clinical research. It looks at the origins of quality management and auditing and explains key definitions related to quality management in clinical research, quality control (QC) and QA as well as why QC and QA must be clearly distinguished. Possible follow-up activities, such as corrections, corrective and preventive actions, are also defined and how they relate to QC and QA is described. Effective quality management systems are composed of different components which are presented in this chapter. However, the focus of quality management systems in clinical research extends not only to compliance, documentation and transparency but also to ethics a dimension to be particularly aware of in Good Clinical Practice (GCP) QA. Audit types (e.g. trial-specific and systems audits), audit locations and the time point of audits (e.g. prospective, in-life and retrospective audits) are presented in detail as these variables are determined by the purpose and the aim of an audit. The chapter discusses the value of audits and also addresses the possible downside of auditing. Apart from confirming compliance or uncovering compliance deficiencies, audits provide the basis for continual improvement in that they highlight areas for improvement and, due to the auditors independence from operational functions, help overcome the blind spots. Audits prevent quality management systems from getting rusty and auditees (and auditors!) from getting complacent and they ensure the continued fitness of the company to meet internal and external requirements. 11

14 1. Introduction It can hardly be imagined that anyone would question the contribution and value of quality management to any kind of industry. Quality management helps ensure that processes are standardised, that legal and regulatory requirements are followed, that customer expectations are met, that products are safe and reliable and that organisations are run in an organised and efficient manner. Of course, this is true as well for the pharmaceutical industry. Quality management efforts are undertaken in many areas, from research and development to manufacturing and distribution of pharmaceuticals. The purpose of all quality-enhancing activities in pharmaceutical research and development is to ensure that valid and robust data are generated which prove the drug s safety, efficacy and quality, reflected in the three core areas of the International Conference on Harmonisation (ICH). While this does not mean that the quality of a pharmaceutical product is limited to these three aspects as availability and affordable price may also be of importance, the chapter is focusing on the ICH aspects. In the ICH context, quality stands for pharmaceutical quality, which means that drugs are manufactured following validated and controlled processes, that active pharmaceutical ingredients and excipients are used which meet pre-defined specifications and which are acquired from quality-assured suppliers, and that the final product complies with specifications. None of the three aspects safety, efficacy and quality can be neglected: a drug which is safe and of proven therapeutic efficacy, but which is of inadequate pharmaceutical quality is as harmful as a drug perfectly manufactured and effective but which is unsafe for the patients. And what would justify having a product on the market lacking efficacy? 2. Quality assurance and audits in GXP what do regulations ask for? Good Laboratory Practice (GLP), Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) are quality systems established in pre-clinical research, clinical drug development and manufacturing, respectively. While it is a common feature of these quality systems to ask for an independent quality assurance (QA) function to be established, the necessity for conducting audits or self-inspections is not equally important in the three different GXP areas Good Manufacturing Practice In accordance with Article 6 of the European GMP Directive [1], the manufacturer shall establish and implement an effective pharmaceutical 12

15 quality assurance system, involving the active participation of the management and personnel of the different departments. Article 13 outlines that the manufacturer shall conduct repeated self-inspections as part of the quality assurance system in order to monitor the implementation and respect of good manufacturing practice and to propose any necessary corrective measures. While the European GMP Directive [1] does not request that self-inspections or audits be performed by independent personnel, Chapter 9 of the PIC/S Guide to GMP for Medicinal Products [2] requires that self-inspections [...] be conducted in an independent and detailed way by designated competent person(s) from the company and independent audits by external experts may also be useful Good Laboratory Practice According to the Organisation for Economic Co-operation and Development (OECD) Principles of Good Laboratory Practice [3], the Quality Assurance Programme means a defined system, including personnel, which is independent of study conduct and is designed to assure test facility management of compliance with these Principles of Good Laboratory Practice. The conduct of inspections to determine if all studies are conducted in accordance with these Principles of Good Laboratory Practice is part of QA s responsibilities Good Clinical Practice While ICH GCP [4] requests that systems with procedures that assure the quality of every aspect of the trial [...] be implemented, that the QA function be independent of and separate from routine monitoring or quality control functions, audits are not explicitly requested. If or when sponsors perform audits audits remain a voluntary activity in ICH GCP. The European Clinical Trials Directive [5] mentions quality assurance arrangements which are to be reviewed during inspections, without being more specific about what exactly these activities entail. The European GCP Directive [6] mentions in Article 16 that the trial master file shall provide the basis for the audit by the sponsor s independent auditor and for the inspection by the competent authority 1). 1) It should be noted that ICH GCP is only a Note for Guidance and bears, therefore, less legal weight than a European Directive which has to be transposed into national law of the Member States and is then legally enforceable. However, this does not exclude the possibility that ICH GCP was referred to in some national laws and consequently was legally binding before the European Clinical Trials Directive was transposed into national law. 13

16 Hence, auditing is no longer a voluntary activity, but a mandatory requirement in accordance with the GCP Directive. The need for an independent QA unit and the conduct of audits is also described in the draft Guideline on Monitoring of Compliance with Pharmacovigilance Regulatory Obligations and Pharmacovigilance Inspections [7], published by the European Commission. Surprisingly, the Food and Drug Administration (FDA) neither mandates the establishment of QA units nor the conduct of audits: Clinical trial quality assurance units (QAUs) are not required by regulation. However, many sponsors have clinical QAUs that perform independent audits/data verifications to determine compliance with clinical trial SOPs and FDA regulations. QAUs should be independent of, and separate from, routine monitoring or quality control functions. [8] In summary, establishing independent QA functions and conducting audits are GCP requirements in Europe. Although the FDA is much less explicit, it may generally be considered unwise to ignore the possible contribution of QA to assuring the quality of clinical research. 3. Historical roots of quality management Efforts to produce goods and to provide services of high quality, to assess quality and to impose punishments in case of inadequate quality are not a new phenomenon. One of the first written documents regulating quality goes back to Hammurabi ( BC), a Babylonian king. Under his rule, a code of laws was developed and chiselled into a huge stone stele which was found in 1902 and is now to be seen in the Louvre Museum in Paris. Hammurabi s code comprises 282 laws. Penalties are barbaric by modern standards and include for example burning, drowning, hanging, impalement on a stake, bodily mutilation and monetary fines. The expression an eye for an eye, a tooth for a tooth has come to symbolise the principle behind Hammurabi s code [9, 10]. Some examples [11] are displayed in Table 1. In the late 13 th century in medieval Europe, guilds were responsible for developing strict rules for product and service quality and furthered quality management. Inspection committees enforced the rules by marking flawless goods with a special mark or symbol [12, 13]. This can be considered the start of quality control an activity to assess finished products to evaluate whether they meet pre-established criteria. One of the next important steps was the introduction of sampling techniques for inspection enabling to infer from a small representative sample to the population, thus speeding up quality control processes. With the possibility to evaluate large amounts of data, statistical process control was introduced; a technique in use in many manufacturing organisations. This technique paved the way to focus on improving the production 14

17 Table 1: Excerpts from Hammurabi s Code. No. 218 No. 225 No. 229 No. 232 No. 235 If a physician make a large incision with the operating knife, and kill him [the patient], or open a tumor with the operating knife, and cut out the eye, his hands shall be cut off. If he [the veterinarian] perform a serious operation on an ass or ox, and kill it, he shall pay the owner one-fourth of its value. If a builder build a house for some one, and does not construct it properly, and the house which he built fall in and kill its owner, then that builder shall be put to death. If it ruin goods, he [the builder] shall make compensation for all that has been ruined, and inasmuch as he did not construct properly this house which he built and it fell, he shall re-erect the house from his own means. If a shipbuilder build a boat for some one, and do not make it tight, if during that same year that boat is sent away and suffers injury, the shipbuilder shall take the boat apart and put it together tight at his own expense. The tight boat he shall give to the boat owner. process rather than inspecting the final product by preventing errors instead of correcting them: this was the birth of quality assurance. The benefits of QA soon led to the insight that quality is an attribute that can be managed and this in a double sense. On the one hand, investments in process quality affect the outcome of the product, i.e. quality can be managed. On the other hand, quality is a task of management. The International Organization for Standardization (ISO) standard 9000:2005 [14] describes the responsibility of senior management and emphasises the importance of leadership by top management in implementing and developing quality management. Further development led to the introduction of Total Quality Management (TQM) where quality management principles are applied to all areas within an organisation or company, not just the operational departments but also functions such as human resources, business development, marketing, finance and controlling. 4. Quality Management, Quality Assurance and Quality Control Although ICH GCP includes an extensive glossary on the most important definitions used in GCP, the following thoughts and explanations may be useful. 15

18 4.1. Quality Management ISO 9000:2005 [14] defines quality management as the coordinated activities to direct and control an organisation with regard to quality. None of the GCP regulations, directives or guidance documents, whether from Europe or from the US, mentions the term quality management the absence of this term is striking! Neither the European Clinical Trials [5] or GCP Directives [6] nor the Code of Federal Regulations (CFR) describes the requirement for a comprehensive quality management system in clinical research. While ICH GCP [4] does not contain an explicit definition for quality management, principle 2.13 speaks of systems with procedures that assure the quality of every aspect of the trial. ISO 9000:2005 (as well as other standards of the ISO 9000 family) may be a useful resource when establishing a quality management system in clinical research as it provides comprehensive information for an area which is only scarcely described, if at all, in GCP regulations and guidelines. This must not imply, however, that ISO certification is to be sought in clinical research Quality Assurance According to ISO 9000:2005 [14], QA is defined as the part of quality management focused on providing confidence that quality requirements will be fulfilled. This definition emphasises that QA activities are futureoriented ( will be fulfilled ) and should focus on improving systems and procedures to be followed to ensure that these are set up in such a way that produces a quality result or service. ICH GCP [4] defines QA as all those planned and systematic actions that are established to ensure that the trial is performed and the data are generated, documented (recorded) and reported in compliance with GCP and the applicable regulatory requirement(s). There is no mention that QA is confined to auditing, but QA comprises all activities suitable to ensure that company procedures are designed so that the product or service will comply (in the future) with pre-established quality requirements Quality Control ICH GCP [4] describes Quality Control (QC) as the operational techniques and activities undertaken within the quality assurance system to verify that the requirements for quality of the trial-related activities have been fulfilled. ISO 9000:2005 [14] uses a more precise definition which nicely contrasts the above ISO definition for QA. Quality control is the part of quality management focused on fulfilling quality requirements. Here, the focus is on activities undertaken by operational departments (such as clinical moni- 16

19 toring, project management, data management etc.) to ensure that processes are performed and documents are written in compliance with the trial protocol, Standard Operating Procedures (SOPs) and other procedural documents. In-process QC steps are conducted as part of the daily routine and are a vital component in the overall quality management system. 5. The difference between QC and QA It is important to distinguish clearly between QC activities, which are embedded in the routine functional tasks and are the responsibility of operational staff, and QA activities (e.g. audits), which are conducted by auditors independent of operational functions. While the intention of both activities, QC and QA, is similar, i.e. enhancing quality, the approach to and the impact of their activities are entirely different. QC is focused on confirming as part of routine operational activities that the output of a process complies with pre-established criteria. Useful QC tools are checklists, for example in order to evaluate if informed consent documents contain all necessary elements and comply with all internal and regulatory requirements, and peer review processes in that a second (or third, fourth) employee another pair of eyes reviews documents prior to their finalisation to verify their accuracy, completeness and consistency. Built-in QC steps with short feedback loops guarantee that deficiencies and errors are identified and rectified early, preventing unnecessary delays caused by time-consuming corrections. Also, for example at investigator sites, behaviours and procedures that might compromise the ethical and safe treatment of trial participants are uncovered in a timely manner. These activities help ensure that processes are run efficiently by minimizing the need for corrections and rework; hence, that the things are done right. Doing the right things, however, is what QA should be concerned about. Placing the focus on effectiveness asks for a change of perspective: rather then checking the quality from within a department, QA should apply a holistic view on processes and procedures. Being independent and detached from operational activities, QA auditors are able to see the big picture and are in a position to identify if processes are suitable to produce the desired result at the expected level of quality. QA should assess the overall capability and aptitude of procedures to verify if these are fit for purpose. QA auditors, and also management, need to be aware of the fine line between QC and QA and clearly define respective responsibilities. Often, in companies and organisations where QC activities are insufficiently implemented or even entirely neglected, QA steps in the role of QC and is misused to conduct QC activities, focusing on present compliance with internal and external regulations, instead of assessing procedures for systemic compliance deficiencies, weaknesses or ineffectiveness. 17

20 As a consequence, the much-needed critical and independent review fails to be conducted and the opportunity is missed for establishing processes which inherently lead to future compliance. If this is the case, error correction rather than prevention prevails. The confusion between the two distinct roles of QC and QA is furthered by the fact that both functions have quality in their name and that neither GMP nor GLP clearly distinguishes between QC and QA. However, this should not be an excuse for being similarly fuzzy about QC and QA roles in GCP. 6. Correction, corrective action and preventive action Quality management is unthinkable without corrections, corrective and preventive actions, also in clinical research. Often, follow-up to QC activities or QA audits mandates corrections to deficiencies observed (if corrections are possible at all). Follow-up activities can range from being selective or far-reaching. The following definitions may shed some light: 6.1. Correction and corrective action ISO 9000:2005 [14] describes correction as an action to eliminate a detected nonconformity whereas corrective action is defined as an action to eliminate the cause of a detected nonconformity or other undesirable situation. As a consequence, applying corrective actions is more lasting than simply correcting errors Preventive action According to ISO 9000:2005 [14], preventive action is described as an action to eliminate the cause of a potential nonconformity or other undesirable potential situation. It should be noted that preventive action is taken to prevent occurrence, i.e. preventing an error from happening at all, whereas corrective action is initiated to prevent recurrence, i.e. preventing an error from happening again Corrective and Preventive Action = CAPA Regulatory authorities have recognised that both aspects are to be considered in a quality management system, for example in pharmacovigilance [7]: Particular emphasis should be placed on organisational roles and responsibilities [...] for ensuring corrective and preventive action. Corrective and Preventive Action (CAPA) is not a new concept in the pharmaceutical 18

European Forum for Good Clinical Practice Audit Working Party

European Forum for Good Clinical Practice Audit Working Party European Forum for Good Clinical Practice Audit Working Party REVISION OF THE ENGAGE 1 AUDITING GUIDELINE. AN OPTIONAL GUIDELINE FOR GCP COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS AUDITING This document

More information

PHARMACEUTICAL QUALITY SYSTEM Q10

PHARMACEUTICAL QUALITY SYSTEM Q10 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step

More information

The Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor

The Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor The Concept of Quality in Clinical Research Dorota Śwituła Senior Clinical Quality Assurance Advisor 1 Agenda What is quality? How we define quality in clinical research? The standard components of a Quality

More information

Guidance for Industry. Q10 Pharmaceutical Quality System

Guidance for Industry. Q10 Pharmaceutical Quality System Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation

More information

ICH guideline Q10 on pharmaceutical quality system

ICH guideline Q10 on pharmaceutical quality system September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final

More information

The Global Guideline for GCP Audit

The Global Guideline for GCP Audit The Global Guideline for GCP Audit Author: JSQA: Hiroyasu Yamashita, e-mail: hiroyasu-yamashita@ds-pharma.co.jp Reviewed and Acknowledged by: BARQA: Patricia Fitzgerald, e-mail: Patricia.fitzgerald@adamas.co.uk

More information

ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION

ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 038-1 26 March 2012 AIDE-MEMOIRE ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION PIC/S March 2012 Reproduction

More information

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration

More information

INTRODUCTION. This book offers a systematic, ten-step approach, from the decision to validate to

INTRODUCTION. This book offers a systematic, ten-step approach, from the decision to validate to INTRODUCTION This book offers a systematic, ten-step approach, from the decision to validate to the assessment of the validation outcome, for validating configurable off-the-shelf (COTS) computer software

More information

QUAๆASSURANCE IN FINANCIAL AUDITING

QUAๆASSURANCE IN FINANCIAL AUDITING Table of contents Subject Page no. A: CHAPTERS Foreword 5 Section 1: Overview of the Handbook 6 Section 2: Quality Control and Quality Assurance 8 2. Quality, quality control and quality assurance 9 2.1

More information

Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples

Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples 28 February 2012 EMA/INS/GCP/532137/2010 GCP Inspectors Working Group Reflection paper for laboratories that perform the analysis or evaluation of clinical trial Draft agreed by GCP Inspectors Working

More information

CLINICAL TRIALS WITH MEDICINES IN EUROPE

CLINICAL TRIALS WITH MEDICINES IN EUROPE CLINICAL TRIALS WITH MEDICINES IN EUROPE REGULATORY FRAMEWORK FOR CLINICAL TRIALS WITH MEDICINES IN EUROPE The pharmaceutical industry is the most highly regulated sector in Europe. The Commission has

More information

History and Principles of Good Clinical Practice

History and Principles of Good Clinical Practice History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices

More information

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 22 June 2012 EMA/541760/2011 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration with Member

More information

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE ICH E6 GCP: Consolidated Guideline: Investigator 1/7 Institutional Review Board Services ICH HARMONIZED TRIPARTITE GUIDELINE E6: GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE 4. INVESTIGATOR 4.1 Investigator's

More information

Managing Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey

Managing Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey Managing Risk in Clinical Research Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey Aim of the session To explore the risks associated with clinical research and understand how

More information

The Quality System for Drugs in Germany

The Quality System for Drugs in Germany The Quality System for Drugs in Germany Prof. Dr. Harald G. Schweim Head of Department for Drug Regulatory Affairs Institute for Pharmacy, University of Bonn Former President of the German Federal Institute

More information

Clinical Research in Mauritius

Clinical Research in Mauritius BOARD OF INVESTMENT Clinical Research in Mauritius This document provides an informative summary of the procedure to apply for a clinical research protocol in Mauritius. Contents INTRODUCTION... 2 I. APPLICATION

More information

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. Supplier Quality Standard 1.0 Purpose The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. These expectations

More information

What is necessary to provide good clinical data for a clinical trial?

What is necessary to provide good clinical data for a clinical trial? What is necessary to provide good clinical data for a clinical trial? Alain Barrois, Assistant Clinical Trials Operations Manager #EBMT2015 www.ebmt.org Is this a (typical) clinical trial? 2 Agenda Introduction

More information

Auditing as a Component of a Pharmaceutical Quality System

Auditing as a Component of a Pharmaceutical Quality System Auditing as a Component of a Pharmaceutical Quality System Tim Fields Conducting internal audits (or self inspections) and external audits of suppliers and outsourcing operations are key elements of a

More information

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process

More information

Insurance and compensation in the event of injury in Phase I clinical trials

Insurance and compensation in the event of injury in Phase I clinical trials Insurance and compensation in the event of injury in Phase I clinical trials Guidance developed by the Association for the British Pharmaceutical Industry, the BioIndustry Association and the Clinical

More information

UK Implementation of the EU Clinical Trial Directive 2001/20/EC:

UK Implementation of the EU Clinical Trial Directive 2001/20/EC: UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October

More information

This interpretation of the revised Annex

This interpretation of the revised Annex Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE July/August 2011, Vol. 31 No. 4 www.ispe.org Copyright ISPE 2011 The ISPE GAMP Community of Practice (COP) provides its interpretation

More information

Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA

Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA This presentation is the property of DynPort Vaccine Company LLC, a CSC company, and

More information

Validation Consultant

Validation Consultant Personal Data Name Title Validation Consultant Contact jsb-validierung Zwischen den Bächen 9 D 79618 Rheinfelden Tel: +49 7623 79 49 82 Mobile: +49 172 737 84 86 E-Mail: Internet: jsb-val@online.de http://www.jsb-validierung.de

More information

QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH

QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH Martin Valania, Executive Director, Corporate QA and Compliance Introduction Pharmaceutical companies recognize the benefits of carefully managing

More information

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance

More information

Clinical trials regulation

Clinical trials regulation Clinical trials regulation The Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on Medicinal Products for Human Use and Repealing Directive 2001/20/EC an update

More information

Manual 074 Electronic Records and Electronic Signatures 1. Purpose

Manual 074 Electronic Records and Electronic Signatures 1. Purpose 1. Purpose The purpose of this document is to provide an interpretation of FDA 21 CFR Part 11, Electronic Records; Electronic Signatures (ER/ES) and to provide guidance for acceptable practices in the

More information

Computerized System Audits In A GCP Pharmaceutical Laboratory Environment

Computerized System Audits In A GCP Pharmaceutical Laboratory Environment IVTGXP_july06.qxd 6/28/06 1:09 PM Page 36 Computerized System Audits In A GCP Pharmaceutical Laboratory Environment By Maintaining data integrity for both clinical laboratory processes and patient data

More information

Health Canada s GCP Compliance Program. GCP Information Sessions November 2010

Health Canada s GCP Compliance Program. GCP Information Sessions November 2010 Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program GCP Information Sessions November 2010 Objective To describe the role that Health

More information

Sheffield Kidney Institute. Planning a Clinical Trial

Sheffield Kidney Institute. Planning a Clinical Trial Planning a Clinical Trial Clinical Trials Testing a new drug Ethical Issues Liability and Indemnity Trial Design Trial Protocol Statistical analysis Clinical Trials Phase I: Phase II: Phase III: Phase

More information

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,

More information

20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany

20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany 20 & 21 October 2005 Clinical trials Risk issues within a wider Europe Adrien Collovray Life Science Conference 2005 Berlin, Germany Clinical trials EC Directive on clinical trials Insurance Requirements

More information

Official Journal of the European Union. (Acts whose publication is obligatory)

Official Journal of the European Union. (Acts whose publication is obligatory) 27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending

More information

Harmonizing Change Control Processes Globally

Harmonizing Change Control Processes Globally Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses

More information

Audit Report in the framework of the APIC Audit Programme

Audit Report in the framework of the APIC Audit Programme Audit Report in the framework of the APIC Audit Programme Company Location Address Country Subject of Audit Audit Date Auditor (lead) Co-Auditor(s) Participants Signature of Auditor(s) Lead Auditor Co-Auditor

More information

How to implement a Quality Management System

How to implement a Quality Management System How to implement a Quality Management System This whitepaper will help you to implement a Quality Management System (QMS), based on Good Manufacturing Practice (GMP), ISO 9001 or ISO 13485 within your

More information

RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING

RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING July 2006 TABLE OF CONTENTS Page 1. Introduction 2 2. Scope 2 3. Documents to be archived 2 4. Quality of essential documents 10 5.

More information

Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015

Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.

More information

Adoption by GCP Inspectors Working Group for consultation 14 June 2011. End of consultation (deadline for comments) 15 February 2012

Adoption by GCP Inspectors Working Group for consultation 14 June 2011. End of consultation (deadline for comments) 15 February 2012 10 December 2013 EMA/INS/GCP/600788/2011 Compliance and Inspection Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials, with particular

More information

GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES. Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme

GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES. Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme Contents 1. Why good documentation is essential? 2. What constitutes

More information

Empowering the Quality and Regulatory Compliance Functions

Empowering the Quality and Regulatory Compliance Functions Empowering the Quality and Regulatory Compliance Functions Management must take steps to ensure that regulatory and quality compliance is everyone s responsibility. By: J. Glenn George, Kenneth Imler,

More information

Computer System Validation - It s More Than Just Testing

Computer System Validation - It s More Than Just Testing Computer System Validation - It s More Than Just Testing Introduction Computer System Validation is the technical discipline that Life Science companies use to ensure that each Information Technology application

More information

Medical Device Training Program 2015

Medical Device Training Program 2015 Medical Device Training Introduction Supplementary training and education is often overlooked by medical device professionals until it is triggered by an upcoming FDA or Notified Body and/or ISO 13485

More information

A responsible approach to clinical trials. Bioethics in action

A responsible approach to clinical trials. Bioethics in action A responsible approach to clinical trials Bioethics in action What is bioethics? At Novo Nordisk bioethics is the expression used for all ethical issues related to the use of life science technologies

More information

ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE

ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE THIS POLICY OUTLINES THE TOP LEVEL REQUIREMENTS TO SUPPORT PRODUCT QUALITY IN THE DEVELOPMENT, MANUFACTURE AND DISTRIBUTION OF ACTIVE PHARMACEUTICAL

More information

Quality Management in Clinical Trials

Quality Management in Clinical Trials CLINICAL CASE STUDY SERIES Quality Management in Clinical Trials Clinical trials are conducted to collect the data necessary to provide information for academia, industry, and regulators to make decisions

More information

Good Clinical Practice 101: An Introduction

Good Clinical Practice 101: An Introduction Good Clinical Practice 101: An Introduction Presented by: Lester Jao Lacorte, MD Medical Officer Commissioner s Fellow Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological

More information

Good Clinical Laboratory Practice (GCLP) An international quality system for laboratories which undertake the analysis of samples from clinical trials

Good Clinical Laboratory Practice (GCLP) An international quality system for laboratories which undertake the analysis of samples from clinical trials Good Clinical Laboratory Practice (GCLP) An international quality system for laboratories which undertake the analysis of samples from clinical trials Vanessa Grant and Tim Stiles VERSION 2 Published by

More information

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity Michelle Quaye Regulatory Manager, Advanced Therapy Trials University College London Overview The Principles of Good

More information

Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials

Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials 1 2 3 5 August 2011 EMA/INS/GCP/600788/2011 Compliance and Inspection 4 5 6 7 Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials

More information

ISO 9001:2008 STANDARD OPERATING PROCEDURES MANUAL

ISO 9001:2008 STANDARD OPERATING PROCEDURES MANUAL 8200 Brownleigh Drive Raleigh, NC 27617-7423 Phone: (919) 510-9696 Fax: (919) 510-9668 ISO 9001:2008 STANDARD OPERATING PROCEDURES MANUAL ALLIANCE OF PROFESSIONALS & CONSULTANTS, INC. - 1 - Table of Contents

More information

CONCEPT HEIDELBERG. Pharmaceutical Quality Training. Conferences. Services.

CONCEPT HEIDELBERG. Pharmaceutical Quality Training. Conferences. Services. CONCEPT HEIDELBERG Pharmaceutical Quality Training. Conferences. Services. About Us Helping you to Comply with GMP Since our foundation on 1 April 1978, CONCEPT HEIDELBERG has been concentrating on providing

More information

[300] Accounting and internal control systems and audit risk assessments

[300] Accounting and internal control systems and audit risk assessments [300] Accounting and internal control systems and audit risk assessments (Issued March 1995) Contents Paragraphs Introduction 1 12 Inherent risk 13 15 Accounting system and control environment 16 23 Internal

More information

What We Are..! www.ardent-cro.com

What We Are..! www.ardent-cro.com Your Trusted CRO! Regus, Level-2, Connaught Place, Bund Garden Road, Pune-411001, MH, India. Phone: 020-65-31-31-71 Email: ardent@ardent-cro.com Web: What We Are..! Ardent Clinical Research Services is

More information

Implementation of a Quality Management System for Aeronautical Information Services -1-

Implementation of a Quality Management System for Aeronautical Information Services -1- Implementation of a Quality Management System for Aeronautical Information Services -1- Implementation of a Quality Management System for Aeronautical Information Services Chapter IV, Quality Management

More information

QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES

QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 002-3 25 September 2007 RECOMMENDATION ON QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES PIC/S September

More information

Seminario SSFA. New Guideline on Good Pharmacovigilance Practice (GVP) Fare clic per modificare lo stile del sottotitolo dello schema

Seminario SSFA. New Guideline on Good Pharmacovigilance Practice (GVP) Fare clic per modificare lo stile del sottotitolo dello schema Seminario SSFA New Guideline on Good Pharmacovigilance Practice (GVP) Pharmacovigilance Systems and their Quality Systems Milano, 20th April 2012 GIULIA M. VALSECCHI The proposed GVP - Module 1 Guidance

More information

New Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01)

New Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01) Safeguarding public health New Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01) Tony Orme, Senior GDP Inspector Inspection, Enforcement and Standards Division

More information

Appendix 1 Waiver of the requirement for informed consent for a clinical trial in a medical emergency Page 1 of 2

Appendix 1 Waiver of the requirement for informed consent for a clinical trial in a medical emergency Page 1 of 2 Appendix 1 Waiver of the requirement for informed consent for a clinical trial in a medical emergency Page 1 of 2 The Helsinki Committee may approve a clinical trial without the requirement to obtain informed

More information

White paper: FDA Guidance for Industry Update Process Validation

White paper: FDA Guidance for Industry Update Process Validation White paper: FDA Guidance for Industry Update Process Validation In January 2011, the FDA released the final version of its long-awaited update to its Process Validation Guidance for Industry. Since then,

More information

The Study Site Master File and Essential Documents

The Study Site Master File and Essential Documents The Study Site Master File and Essential Documents Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 002 Version number: 1 Effective date: 01 June 2010

More information

THE TRANSFER OF PERSONAL DATA ABROAD

THE TRANSFER OF PERSONAL DATA ABROAD THE TRANSFER OF PERSONAL DATA ABROAD MARCH 2014 THIS NOTE CONSIDERS THE SITUATION OF AN IRISH ORGANISATION OR BUSINESS SEEKING TO TRANSFER PERSONAL DATA ABROAD FOR STORAGE OR PROCESSING, IN LIGHT OF THE

More information

Note that the following document is copyright, details of which are provided on the next page.

Note that the following document is copyright, details of which are provided on the next page. Please note that the following document was created by the former Australian Council for Safety and Quality in Health Care. The former Council ceased its activities on 31 December 2005 and the Australian

More information

EUROPEAN INDUSTRIAL PHARMACISTS GROUP

EUROPEAN INDUSTRIAL PHARMACISTS GROUP EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guide to Good Regulatory Practice Acknowledgments: Valérie LACAMOIRE, Conseil Central de la section B de l Ordre des Pharmaciens Kelsey MOWER, Industrial Pharmacists

More information

Job Profile Clinical Research Associate III (CRA)

Job Profile Clinical Research Associate III (CRA) PART 1 - PROFILE You are an experienced CRA with a strong background in Clinical Research who is passionate about drug development and are seeking a challenging and rewarding career in a quality focussed

More information

Signature Requirements for the etmf

Signature Requirements for the etmf Wingspan Technology Signature Requirements for the etmf A Regulatory and Technological Assessment Kathie Clark Director, Product Management Wingspan Technology 1 November 2012 Signature Requirements for

More information

What is the correct title of this publication? What is the current status of understanding and implementation?

What is the correct title of this publication? What is the current status of understanding and implementation? GMP Rules and Guidelines in 2013 for Computer System Validation / Computerises Systems / Electronic Records and Signatures/ IT Infrastructure and Application Compliance: What is the correct title of this

More information

FINAL DOCUMENT. Guidelines for Regulatory Auditing of Quality Management Systems of Medical Device Manufacturers Part 1: General Requirements

FINAL DOCUMENT. Guidelines for Regulatory Auditing of Quality Management Systems of Medical Device Manufacturers Part 1: General Requirements GHTF/SG4/N28R4:2008 FINAL DOCUMENT Title: Guidelines for Regulatory Auditing of Quality Management Systems of Medical Device Manufacturers Authoring Group: GHTF Study Group 4 Endorsed by: The Global Harmonization

More information

GCP INSPECTORS WORKING GROUP REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS

GCP INSPECTORS WORKING GROUP <DRAFT> REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS European Medicines Agency London, 17 October 2007 Doc. Ref. EMEA/505620/2007 GCP INSPECTORS WORKING GROUP REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS

More information

Ordinance on Specialised Waste Management Companies (Entsorgungsfachbetriebeverordnung - EfbV) *) of 10 September 1996

Ordinance on Specialised Waste Management Companies (Entsorgungsfachbetriebeverordnung - EfbV) *) of 10 September 1996 Ordinance on Specialised Waste Management Companies (Entsorgungsfachbetriebeverordnung - EfbV) *) of 10 September 1996 The Federal Government, having heard the parties concerned, and pursuant to Article

More information

The APIC Audit Programme

The APIC Audit Programme The APIC Audit Programme Standardised Cost APIC-certified GMP Compliance A Third Party Audit Programme for API Manufactureres An Initiative of APIC in co-operation with CONCEPT HEIDELBERG A sector group

More information

Pharmaceutical Quality Management System: Current Concept

Pharmaceutical Quality Management System: Current Concept Pharmaceutical Quality Management System: Current Concept Neetu Dubey 1, *, Himanshu Gupta 3, R.K. Sharma 2, Nitin Dubey 1, Nidhi Dubey 4 1. IPS Academy, Indore, Madhya Pradesh, India. 2. Prestige Institute

More information

Z.A.S. Archive- and informationsmanagement

Z.A.S. Archive- and informationsmanagement Z.A.S. Archive- and informationsmanagement Presentation at SAG Scientific Archivists Group Spring Conference in Basel 11 June 2010 Electronic Archiving in a GXP-regulated environment Author: Bernd Mohnsame

More information

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION April 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES:

More information

EXECUTIVE SAFETY LEADERSHIP

EXECUTIVE SAFETY LEADERSHIP EXECUTIVE SAFETY LEADERSHIP EXECUTIVE SUMMARY This guide offers clear explanations of health and safety concepts that are important to executives and board members, and provides practical solutions that

More information

PROPOSED DOCUMENT. Quality management system Medical devices Nonconformity Grading System for Regulatory Purposes and Information Ex-change

PROPOSED DOCUMENT. Quality management system Medical devices Nonconformity Grading System for Regulatory Purposes and Information Ex-change AHWP/WG3/P001:2013 PROPOSED DOCUMENT Title: Quality management system Medical devices Nonconformity Grading System for Regulatory Purposes and Information Ex-change Author: AHWP Work Group 3 Date: 13 November

More information

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Kevin O Donnell PhD Market Compliance Manager, IMB PDA / FDA Conference Pharmaceutical

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL VERSION 4.1

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL VERSION 4.1 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, SANCO/D/6/SF/mg/ddg1.d.6(2013) IMPORTATION OF ACTIVE SUBSTANCES

More information

GxP Process Management Software. White Paper: Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations

GxP Process Management Software. White Paper: Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations GxP Process Management Software : Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations Most FDA violations involve one of the following: Not having procedures in a regulated area

More information

PROJECT AUDIT METHODOLOGY

PROJECT AUDIT METHODOLOGY PROJECT AUDIT METHODOLOGY 1 "Your career as a project manager begins here!" Content Introduction... 3 1. Definition of the project audit... 3 2. Objectives of the project audit... 3 3. Benefit of the audit

More information

Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations

Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

The use of computer systems

The use of computer systems Technology Update Computer Systems Validation, Part 1 Software Purchase and GCP Compliance Teri Stokes Teri Stokes, PhD, is senior consultant and director of GXP International, 131 Sudbury Road, Concord,

More information

SCIENTIFIC SUBSTANTIATION OF STANDARD OPERATIONAL PROCEDURES ROLE IN QUALITY ASSURANCE SYSTEM IN CLINICAL DRUG TRIALS

SCIENTIFIC SUBSTANTIATION OF STANDARD OPERATIONAL PROCEDURES ROLE IN QUALITY ASSURANCE SYSTEM IN CLINICAL DRUG TRIALS UDC 615:519.076 Dobrova V. Ye., Zupanets K. O., Ratushna K. L. National University of Pharmacy SCIENTIFIC SUBSTANTIATION OF STANDARD OPERATIONAL PROCEDURES ROLE IN QUALITY ASSURANCE SYSTEM IN CLINICAL

More information

Implementation of ANSI/AAMI/IEC 62304 Medical Device Software Lifecycle Processes.

Implementation of ANSI/AAMI/IEC 62304 Medical Device Software Lifecycle Processes. Implementation of ANSI/AAMI/IEC 62304 Medical Device Software Lifecycle Processes.. www.pharmout.net Page 1 of 15 Version-02 1. Scope 1.1. Purpose This paper reviews the implementation of the ANSI/AAMI/IEC

More information

APES 320 Quality Control for Firms

APES 320 Quality Control for Firms APES 320 Quality Control for Firms APES 320 Quality Control for Firms is based on International Standard on Quality Control (ISQC 1) (as published in the Handbook of International Auditing, Assurance,

More information

CORPORATE QUALITY MANUAL

CORPORATE QUALITY MANUAL Corporate Quality Manual Preface The following Corporate Quality Manual is written within the framework of ISO 9001:2008 Quality System by the employees of CyberOptics. CyberOptics recognizes the importance

More information

Sector Development Ageing, Disability and Home Care Department of Family and Community Services (02) 8270 2218

Sector Development Ageing, Disability and Home Care Department of Family and Community Services (02) 8270 2218 Copyright in the material is owned by the State of New South Wales. Apart from any use as permitted under the Copyright Act 1968 and/or as explicitly permitted below, all other rights are reserved. You

More information

Best Practice In A Change Management System

Best Practice In A Change Management System Quality & Compliance Associates, LLC Best Practice In A Change Management System President Quality & Compliance Associates, LLC Change Control and Its Role in a Continuous Improvement Environment 3 Benefits

More information

Nuclear Safety Council Instruction number IS-19, of October 22 nd 2008, on the requirements of the nuclear facilities management system

Nuclear Safety Council Instruction number IS-19, of October 22 nd 2008, on the requirements of the nuclear facilities management system Nuclear Safety Council Instruction number IS-19, of October 22 nd 2008, on the requirements of the nuclear facilities management system Published in the Official State Gazette (BOE) number 270 of November

More information

Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions

Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions WELCOME Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions Contents: Introduction GMP Audit GMP Audit plan GMP Auditing

More information

Data Management Unit Research Institute for Health Sciences, Chiang Mai University

Data Management Unit Research Institute for Health Sciences, Chiang Mai University Data Management Unit Research Institute for Health Sciences, Chiang Mai University Clinical Data Management is the process of handling data from clinical trials. The inherent goal of any clinical data

More information